T. Seufferlein provides molecular insights in the biology of pancreatic cancer which opens-up opportunities for testing already existing and new drugs. He explains the results from the study with novel immunotherapeutic agent IMM 101; the study allowed recruitment of patients with WHO PS 2, the real-life population - less ideal one from usual clinical trial situation. Therefore, the results achieved are even more important. Furthermore, he elaborates the results from the study with PEGPH20, an agent with novel mechanism of action and digs into other new agents/strategies on horizon in this setting.